Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Current Opinion in Genetics & Development
|
August 22, 2006
Hematopoietic stem cell self-renewal
Omobolaji O Akala, Michael F Clarke
CPT: Pharmacometrics & Systems Pharmacology
|
June 12, 2024
A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology
Raunak Dutta, Aparna Mohan, Jacqueline Buros-Novik, et al.
Nature
|
April 18, 2008
Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors
Omobolaji O Akala, In-Kyung Park, Dalong Qian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2025
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18
Graham L Cohen, Corlia Coetzee, Cathryn A Walton, et al.
Journal of Hematology & Oncology
|
June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
Quchang Ouyang, Jordi Rodon, Yan Liang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Current Opinion in Genetics & Development
|
August 22, 2006
Hematopoietic stem cell self-renewal
Omobolaji O Akala, Michael F Clarke
CPT: Pharmacometrics & Systems Pharmacology
|
June 12, 2024
A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology
Raunak Dutta, Aparna Mohan, Jacqueline Buros-Novik, et al.
Nature
|
April 18, 2008
Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors
Omobolaji O Akala, In-Kyung Park, Dalong Qian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2025
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18
Graham L Cohen, Corlia Coetzee, Cathryn A Walton, et al.
Journal of Hematology & Oncology
|
June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
Quchang Ouyang, Jordi Rodon, Yan Liang, et al.
Page
of 1